Diligence memo · auto-generated · as of July 2, 2026

Efficas Inc

Efficas Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Efficas Inc operates in Biotechnology, based in Boulder.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Efficas Inc has raised $3.9M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.2M on 2009-03-10.

Most recent recorded round closed around 2009-03-10.

Valuation (modeled)modeled

Provath models Efficas Inc at approximately $141M (range $2.3M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.36× the median modeled value of Seed Biotechnology companies in 2007–2009 (47 peers) — value vs value, same stage and era. Within the normal band (136% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 17.3 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 15.8× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 39% of Biotechnology peers (4293 compared).

Modeled value ranks above 65% of those peers.

Closest niche peers: Bioassets Development Corp, Aubrey Inc, EndoMetabolic Solutions, Inc., Targegen Inc, Promethean Surgical Devices, Inc..

Peoplefiled

13 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.